Patent · US Active

Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation

US9254309B2 · kind B2 · utility

0Cited by
15References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 26, 2013
Grant dateFeb 9, 2016
Priority date
Expiry dateSep 23, 2033

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K38/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.